 |
|
|
| |
Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial
|
| |
| |
EACS 2023 Oct 18-21 Warsaw
Frank A. Post1; Giovanni Di Perri2; Douglas Cunningham3; Cristina Mussini4; Jürgen K. Rockstroh5; Todd A. Correll6; Ciaran J. McMullan6; Michelle Karten6; Ying Zhang6; Kathleen Squires6;
Michelle C. Fox6; Mary Pisculli6*
1King's College Hospital NHS Foundation Trust, London, UK; 2University of Torino, Torino, Italy;
3Pueblo Family Physicians, Phoenix, AZ, USA; 4University of Modena and Reggio Emilia, Modena, Italy; 5Department of Medicine I, University Hospital Bonn, Bonn, Germany; 6Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
